A5055570963- Bone health and treatments
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- PARP inhibition in cancer therapy
- HIV/AIDS Research and Interventions
- HIV, Drug Use, Sexual Risk
- Diabetes Management and Research
- Economic and Financial Impacts of Cancer
- Diabetes Management and Education
- Adolescent Sexual and Reproductive Health
- Cancer, Hypoxia, and Metabolism
- DNA Repair Mechanisms
- Diabetes, Cardiovascular Risks, and Lipoproteins
- LGBTQ Health, Identity, and Policy
Tsinghua University
2023
Research Foundation of The City University of New York
2017
Eisai (United States)
2012
Albert Einstein College of Medicine
2007
Montefiore Medical Center
2007
OBJECTIVE To determine the impact of a health system–wide primary care diabetes management system, which included targeted guidelines for type 2 (T2DM) and prediabetes (dysglycemia) screening, on detection previously undiagnosed dysglycemia cases. RESEARCH DESIGN AND METHODS Intervention electronic record (EHR)–based decision support standardized providers staff training using American Diabetes Association screening. Using EHR data, we identified 40,456 adults without T2DM or recent...
Abstract The majority of patients with late-stage breast cancer develop distal bone metastases. microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation...
Objectives. Studies continue to document that people with human immunodeficiency virus (HIV) experience discrimination in their interactions the health-care system, which can have negative implications for maintaining continuity care and outcomes. We explored patient characteristics associated perceived whether these experiences are system quality ratings a survey of severely disadvantaged HIV who at great risk inconsistent access appropriate health care. Methods. Five hundred twenty-three...
Background: In studies examining the use of human immunodeficiency virus (HIV) health services, researchers often subjects' self-reported measures. Agreement between a subject's self-reports and medical records in marginalized populations is uncertain, yet important to understand, as this population disproportionately affected by HIV. Methods: We sought examine agreement self-report record care utilization Using cross-sectional study, we studied 428 unstably housed HIV-infected adults New...
<p>Metabolomics of primary tumors vs bone metastasis</p>
<p>Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).</p>
<div>Abstract<p>The majority of patients with late-stage breast cancer develop distal bone metastases. The microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts....
<p>Metabolomics of macrophages vs osteaoclasts</p>
<p>Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).</p>
<p>Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).</p>
<p>Metabolomics of macrophages vs osteaoclasts</p>
<p>Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).</p>
<p>Metabolomics of primary tumors vs bone metastasis</p>
<p>Supplementary Video S1 is related to Figure 5 (Vehicle-only group).</p>
<p>Supplementary Video S1 is related to Figure 5 (Vehicle-only group).</p>
<p>Supplementary Video S2 is related to Figure 5 (Olaparib-only group).</p>
<div>Abstract<p>The majority of patients with late-stage breast cancer develop distal bone metastases. The microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating metastatic cancer. Here, we observed that osteoclasts reduced sensitivity cells DNA damaging agents, including cisplatin PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts....
<p>Supplemental Figures 1-7</p>
<p>Supplemental Figures 1-7</p>
<p>Supplementary Video S2 is related to Figure 5 (Olaparib-only group).</p>
e16521 Background: The costs of treating patients with metastatic breast cancer (mBC) have been examined in several studies, but there is very limited information regarding healthcare resource utilization (HCRU) and mBC among Medicaid beneficiaries. objective this study was to characterize HCRU women mBC. Methods: Women who were younger than 65 identified using Thomson Reuters’ claims data from 12-13 states (2005-2009). Overall medical estimated those compared (BC) without metastasis the...